Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group

Journal
Frontiers in Immunology
ISSN
1664-3224
Date Issued
2022
Author(s)
Alejandro Escobar
Felipe E. Reyes-López
Mónica L. Acevedo
Luis Alonso-Palomares
Fernando Valiente-Echeverría
Ricardo Soto-Rifo
Hugo Portillo
Jimena Gatica
Ivan Flores
Estefanía Nova-Lamperti
Carlos Barrera-Avalos
María Rosa Bono
Leonardo Vargas
Valeska Simon
Elias Leiva-Salcedo
Daniel Valdés
Ana M. Sandino
Mónica Imarai
Claudio Acuña-Castillo
Type
Resource Types::text::journal::journal article
Scopus ID
2-s2.0-85124612312
WoS ID
WOS:000756934800001
DOI
URL
URL Institutional Repository
Abstract
<jats:p>CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.</jats:p>
Cite this document
Escobar, A., Reyes-López, F. E., Acevedo, M. L., Alonso-Palomares, L., Valiente-Echeverría, F., Soto-Rifo, R., Portillo, H., Gatica, J., Flores, I., Nova-Lamperti, E., Barrera-Avalos, C., Bono, M. R., Vargas, L., Simon, V., Leiva-Salcedo, E., Vial, C., Hormazabal, J., Cortes, L. J., Valdés, D., … Acuña-Castillo, C. (2022). Evaluation of the immune response induced by coronavac 28-day schedule vaccination in a healthy population group. Frontiers in Immunology, 12, 766278. https://doi.org/10.3389/fimmu.2021.766278
Project(s)
Subjects
coronavac

; 

sars-cov-2

; 

herd immunity

; 

neutralizing antibodies

; 

covid-19

; 

vaccine

; 

immunological memory

; 

adult

; 

antibodies, neutralizing

; 

antibodies, viral

; 

b-lymphocytes

; 

biomarkers

; 

chile

; 

covid-19

; 

covid-19 vaccines

; 

female

; 

granzymes

; 

healthy volunteers

; 

humans

; 

immunity, cellular

; 

immunity, humoral

; 

immunization schedule

; 

immunogenicity, vaccine

; 

immunologic memory

; 

interferon-gamma

; 

male

; 

middle aged

; 

sars-cov-2

; 

spike glycoprotein, coronavirus

; 

time factors

; 

treatment outcome

; 

coronavac

; 

coronavirus spike glycoprotein

; 

cytokine

; 

gamma interferon

; 

granzyme b

; 

immunoglobulin g

; 

immunoglobulin m

; 

interleukin 10

; 

interleukin 12

; 

interleukin 1beta

; 

interleukin 2

; 

interleukin 6

; 

interleukin 8

; 

neutralizing antibody

; 

polyethyleneimine

; 

polysorbate 20

; 

structural protein

; 

tumor necrosis factor

; 

virus spike protein

; 

biological marker

; 

gamma interferon

; 

granzyme

; 

gzmb protein, human

; 

ifng protein, human

; 

neutralizing antibody

; 

spike protein, sars-cov-2

; 

virus antibody

; 

adult

; 

article

; 

blood sampling

; 

cellular immunity

; 

clinical article

; 

coronavirus disease 2019

; 

coronavirus infection

; 

cytometric bead array

; 

drug effect

; 

enzyme linked immunosorbent assay

; 

enzyme linked immunospot assay

; 

female

; 

fetal bovine serum

; 

flow cytometry

; 

hek293t cell line

; 

human

; 

human experiment

; 

id50

; 

immune response

; 

immunity

; 

immunoblotting

; 

immunological memory

; 

informed consent

; 

luciferase assay

; 

male

; 

observational study

; 

peripheral blood mononuclear cell

; 

polymerase chain reaction

; 

protein purification

; 

severe acute respiratory syndrome coronavirus 2

; 

size exclusion chromatography

; 

vaccination

; 

virus neutralization

; 

administration and dosage

; 

b lymphocyte

; 

blood

; 

chile

; 

humoral immunity

; 

immunization

; 

immunology

; 

metabolism

; 

middle aged

; 

normal human

; 

prevention and control

; 

time factor

; 

treatment outcome

; 

vaccine immunogenicity

; 

virology